Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beta Bionics (BBNX) Shares Outstanding (Diluted Average) (2023 - 2025)

Historic Shares Outstanding (Diluted Average) for Beta Bionics (BBNX) over the last 3 years, with Q3 2025 value amounting to $43.6 million.

  • Beta Bionics' Shares Outstanding (Diluted Average) rose 55511.68% to $43.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 55511.68%. This contributed to the annual value of $6.4 million for FY2024, which is 2001.21% up from last year.
  • Per Beta Bionics' latest filing, its Shares Outstanding (Diluted Average) stood at $43.6 million for Q3 2025, which was up 55511.68% from $43.4 million recorded in Q2 2025.
  • Beta Bionics' 5-year Shares Outstanding (Diluted Average) high stood at $43.6 million for Q3 2025, and its period low was $5.3 million during Q4 2023.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $18.5 million, with a median of $6.5 million in 2024.
  • In the last 5 years, Beta Bionics' Shares Outstanding (Diluted Average) surged by 2001.21% in 2024 and then skyrocketed by 61064.5% in 2025.
  • Beta Bionics' Shares Outstanding (Diluted Average) (Quarter) stood at $5.3 million in 2023, then increased by 20.01% to $6.4 million in 2024, then skyrocketed by 585.52% to $43.6 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $43.6 million in Q3 2025, compared to $43.4 million in Q2 2025 and $30.7 million in Q1 2025.